---
title: "Beam Therapeutics tops Q4 profit estimates, signs financing deal"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/276730924.md"
datetime: "2026-02-24T12:10:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276730924.md)
  - [en](https://longbridge.com/en/news/276730924.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276730924.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/276730924.md) | [English](https://longbridge.com/en/news/276730924.md)


# Beam Therapeutics tops Q4 profit estimates, signs financing deal

)

Overview

-   Biotechnology firm reported Q4 EPS and net income beat analyst expectations
-   Company entered strategic financing agreement with Sixth Street for up to $500 mln
-   Company expanded liver-targeted genetic disease franchise with BEAM-304 for PKU

Outlook

-   Beam expects to file IND for BEAM-304 in 2026
-   Beam plans BLA submission for risto-cel by year-end 2026
-   Beam anticipates updated BEAM-302 data by Q1 2026

Result Drivers

-   BEAM-304 EXPANSION - Beam expanded its liver-targeted genetic disease franchise with BEAM-304 for PKU, leveraging base editing technology to address mutations in the PAH gene
-   STRATEGIC FINANCING - Beam secured a strategic financing agreement with Sixth Street for up to $500 mln to support the launch of risto-cel in SCD Company press release:

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

### Q4 $114.11

License mln

and

Collabor

ation

Revenue

Q4 EPS Beat $2.33 -$0.99

(15

Analysts

)

Q4 Net Beat $244.30 -$91.17

Income mln mln (15

Analysts

)

Q4 Beat -$17.45 -$117.30

Operatin mln mln (14

g Income Analysts

)

Q4 Beat $244.30 -$95.99

Pretax mln mln (13

Profit Analysts

)

### Q4 $131.55

Operatin mln

g

Expenses

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 17 “strong buy” or “buy”, 2 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the biotechnology & medical research peer group is “buy”
-   Wall Street’s median 12-month price target for Beam Therapeutics Inc is $45.00, about 58.8% above its February 23 closing price of $28.33 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### 相關股票

- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Beam Therapeutics (BEAM.US)](https://longbridge.com/zh-HK/quote/BEAM.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)

## 相關資訊與研究

- [Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference](https://longbridge.com/zh-HK/news/279535511.md)
- [BUZZ-CytomX retreats ahead of planned $250 mln equity raise after promising cancer drug data](https://longbridge.com/zh-HK/news/279463333.md)
- [Trevi Therapeutics Maps Phase III Path and Runway](https://longbridge.com/zh-HK/news/279703997.md)
- [Dyadic Applied Hikes on Integrated Pact](https://longbridge.com/zh-HK/news/279283757.md)
- [Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/zh-HK/news/279226861.md)